New eczema drug shows promise in Mid-Stage trial
NCT ID NCT07175233
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 31 times
Summary
This study tests a new drug called SIM0278 in 184 adults with moderate to severe atopic dermatitis (eczema). Participants will receive one of three doses of the drug or a placebo to see if it reduces skin redness, itching, and rash. The main goal is to measure improvement in eczema severity after 16 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hangzhou First People's Hospital, School of Medicine , West Lake University
Hangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of China Medical University
Shenyang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.